These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
596 related articles for article (PubMed ID: 31595147)
21. Construction and validation of a novel immunological model to predict prognosis in pancreatic ductal adenocarcinoma. Liu J; He M Int Immunopharmacol; 2024 Jun; 134():112266. PubMed ID: 38761784 [TBL] [Abstract][Full Text] [Related]
22. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma. Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324 [TBL] [Abstract][Full Text] [Related]
23. A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma. Zhou C; Wang S; Zhou Q; Zhao J; Xia X; Chen W; Zheng Y; Xue M; Yang F; Fu D; Yin Y; Atyah M; Qin L; Zhao Y; Bruns C; Jia H; Ren N; Dong Q Front Oncol; 2019; 9():1160. PubMed ID: 31781487 [No Abstract] [Full Text] [Related]
24. Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas. Zhuang H; Wang S; Chen B; Zhang Z; Ma Z; Li Z; Liu C; Zhou Z; Gong Y; Huang S; Hou B; Chen Y; Zhang C Front Immunol; 2021; 12():790661. PubMed ID: 34925373 [TBL] [Abstract][Full Text] [Related]
25. A protein-based prognostic model for pancreatic ductal adenocarcinoma: Construction and validation. Xu Y; Wang Y; Chen Q; Yao T; Qiu J; Ni L; Chen H; Liang T Pancreatology; 2023 Dec; 23(8):1003-1013. PubMed ID: 37923686 [TBL] [Abstract][Full Text] [Related]
26. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma. Kandimalla R; Tomihara H; Banwait JK; Yamamura K; Singh G; Baba H; Goel A Clin Cancer Res; 2020 Jul; 26(14):3641-3648. PubMed ID: 32234757 [TBL] [Abstract][Full Text] [Related]
27. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma. Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153 [TBL] [Abstract][Full Text] [Related]
28. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes. Zhao L; Zhao H; Yan H BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660 [TBL] [Abstract][Full Text] [Related]
30. Construction of mRNA prognosis signature associated with differentially expressed genes in early stage of stomach adenocarcinomas based on TCGA and GEO datasets. Jiang F; Lin H; Yan H; Sun X; Yang J; Dong M Eur J Med Res; 2022 Oct; 27(1):205. PubMed ID: 36253873 [TBL] [Abstract][Full Text] [Related]
31. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival. Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700 [TBL] [Abstract][Full Text] [Related]
32. Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma. Yan TT; Fu XL; Li J; Bian YN; Liu DJ; Hua R; Ren LL; Li CT; Sun YW; Chen HY; Fang JY; Hong J Oncotarget; 2015 Nov; 6(35):37028-42. PubMed ID: 26498693 [TBL] [Abstract][Full Text] [Related]
33. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma. Zhang SR; Li H; Wang WQ; Jin W; Xu JZ; Xu HX; Wu CT; Gao HL; Li S; Li TJ; Zhang WH; Xu SS; Ni QX; Yu XJ; Liu L Eur J Surg Oncol; 2019 May; 45(5):769-775. PubMed ID: 30416079 [TBL] [Abstract][Full Text] [Related]
34. DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. Sun J; Bi F; Yang Y; Zhang Y; Jin A; Li J; Lin Z Oncol Rep; 2017 Feb; 37(2):857-864. PubMed ID: 27959420 [TBL] [Abstract][Full Text] [Related]
35. Development and Verification of a novel cuproptosis- and immune-associated based prognostic genetic signature for pancreatic ductal adenocarcinoma. Xu X; Liang JH; Xu QC; Yin XY Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102089. PubMed ID: 36707046 [TBL] [Abstract][Full Text] [Related]
37. Neutrophils infiltrating pancreatic ductal adenocarcinoma indicate higher malignancy and worse prognosis. Wang Y; Fang T; Huang L; Wang H; Zhang L; Wang Z; Cui Y Biochem Biophys Res Commun; 2018 Jun; 501(1):313-319. PubMed ID: 29738769 [TBL] [Abstract][Full Text] [Related]
38. Identification of a robust functional subpathway signature for pancreatic ductal adenocarcinoma by comprehensive and integrated analyses. Wang P; Zhang C; Li W; Zhai B; Jiang X; Reddy S; Jiang H; Sun X Cell Commun Signal; 2020 Mar; 18(1):34. PubMed ID: 32122386 [TBL] [Abstract][Full Text] [Related]
39. Combining single-cell and bulk RNA sequencing, NK cell marker genes reveal a prognostic and immune status in pancreatic ductal adenocarcinoma. Ouyang Y; Shen R; Chu L; Fu C; Hu W; Huang H; Zhang Z; Jiang M; Chen X Sci Rep; 2024 Jul; 14(1):15037. PubMed ID: 38951569 [TBL] [Abstract][Full Text] [Related]
40. Glycolysis-Based Genes Associated with the Clinical Outcome of Pancreatic Ductal Adenocarcinoma Identified by The Cancer Genome Atlas Data Analysis. Tian G; Li G; Liu P; Wang Z; Li N DNA Cell Biol; 2020 Mar; 39(3):417-427. PubMed ID: 31968179 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]